Screener
Jazz Pharmaceuticals JAZZ Equity Method Investments
Equity Method Investments at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount.
The source filing: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:09 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001232524-26-000025
As of March 31, 2026 and December 31, 2025, the carrying amount of investments measured using the measurement alternative for equity investments without a readily determinable fair value was $4.3 million. The carrying amount, which is recorded within other non-current assets, is based on the latest observable transaction price.
Item 1.Financial Statements
FAQ
- What is Jazz Pharmaceuticals's equity method investments?
- Jazz Pharmaceuticals (JAZZ) reported equity method investments of $4.3M in Q1 2026.
- How has Jazz Pharmaceuticals's equity method investments changed year-over-year?
- Jazz Pharmaceuticals's equity method investments decreased by 0.0% year-over-year, from $4.3M to $4.3M.
- What is the long-term trend for Jazz Pharmaceuticals's equity method investments?
- Over 3 years (2022 to 2025), Jazz Pharmaceuticals's equity method investments has grown at a -7.9% compound annual growth rate (CAGR), from $5.5M to $4.3M.
- What does equity method investments mean?
- Investments in unconsolidated affiliates and joint ventures where the company has significant influence (typically 20-50% ownership), carried at proportional book value.
Ask your AI about Jazz Pharmaceuticals's equity method investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude